Bankers Urge Private Equity to Keep IPO Revival Going in 2026

Bankers are urging private-equity firms to accelerate IPO activity in 2026 by taking a broad swath of portfolio companies public, citing a backlog of sizable companies across sectors from industrials to tech after extended post-pandemic holding periods. A renewed wave of listings would expand public supply, provide exit liquidity for buyout firms and create new investable opportunities, with implications for equity issuance, valuation formation and secondary-market flows.

Analysis

Market structure: The primary beneficiaries are global bookrunners and capital-markets desks (underwriting fees, trading flow) — think Goldman Sachs (GS) and Morgan Stanley (MS) — plus secondary-market liquidity providers and ETFs that track new issuances. Losers include late-stage private investors facing valuation resets, highly leveraged PE vehicles that rely on hold-period arbitrage, and recently listed high-multiple growth names that compete for investor dollars. Supply/demand shifts: a sustained 2026 IPO wave will increase free float (potentially +$50–$150bn of new equity over 6–12 months), pressuring near-term demand and compressing first-year aftermarket returns by an estimated 10–30% versus pre-IPO valuations.

Risk assessment: Tail risks include a macro recession that halts deals, regulatory changes forcing greater PE fee/transparency (triggering markdowns), or a concentrated lock-up selling cycle that spikes equity volatility. Immediate (days) reactions will be deal announcements; short-term (weeks–months) will see underwriting revenue revisions and IB rerating; long-term (quarters) a structural re-pricing of late-stage private valuations. Hidden dependencies: secondary-placement activity, sponsor-led tender offers, and fee-competition between banks can dilute revenue upside even if IPO counts rise. Key catalysts: accelerated Fed easing, >$50bn rolling IPO volume, or tighter SEC rules on private-market disclosures.

Trade implications: Direct plays favor selective long exposure to top bookrunners and an ETF exposure to the IPO cohort while hedging beta; use calendar-aligned options to capture 2026 window. Relative-value: long IBs vs short high-multiple growth/innovation ETFs to harvest rotation from private-to-public supply. Cross-asset: expect modest upward pressure on IG corporate spreads and cyclical commodity demand if industrial IPOs fund capex.

Contrarian: The market assumes banks capture most upside; consensus underestimates fee compression from competition and the limited scale of many 2026 listings relative to global market cap. Historical parallels (post-2009 and 2013 IPO waves) show poor first-year returns for many new issuers — a setup for tactical shorting or put-credit strategies on crowded segments. Unintended consequence: a glut of mid-sized IPOs could create buying opportunities in 6–12 months as weak listings get oversold despite solid fundamentals.

Key Decisions for Investors

• Establish a 2–3% portfolio position (total) long in top-tier bookrunners: GS (ticker GS) and Morgan Stanley (ticker MS) split 60/40; time horizon 9–18 months. Add another 1% if combined sector underwriting revenue guidance prints +10% q/q or if rolling 6-month IPO issuance > $50bn.
• Allocate 1–2% to the Renaissance IPO ETF (ticker IPO) to capture new-issue exposure; set strict rules: trim +30% within 9–12 months, stop-loss -15%. Increase to 3% only if ETF inflows exceed $500m over any 3-month period.
• Buy defined-risk call spreads on GS and MS expiring Jan 2027 (buy near-the-money, sell ~25% OTM) sized 0.5% portfolio each to lever upside while capping premium; deploy immediately and scale up if IPO count in a rolling 60-day window exceeds 25 priced deals.
• Hedge/short tactical: buy 3-month put spreads on Russell 2000 Growth ETF (IWO) sized 0.5–1% if >30 IPOs price in any 60-day window or IV spikes >20% — alternatively initiate a 0.5–1% directional short on ARK Innovation ETF (ARKK) via puts if sentiment chases late-stage listings at >30x forward sales.